A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up

Objective: To evaluate the efficacy and long-term safety of vilazodone in children and adolescent outpatients with major depressive disorder (MDD). Methods: Children and adolescents aged 7–17 years of age with MDD were randomized 2:2:1 to 8 weeks of double-blind placebo, vilazodone 15 or 30 mg/day o...

Descripción completa

Detalles Bibliográficos
Autores principales: Findling, Robert L., McCusker, Emily, Strawn, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409584/
https://www.ncbi.nlm.nih.gov/pubmed/32460523
http://dx.doi.org/10.1089/cap.2019.0176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409584/
https://www.ncbi.nlm.nih.gov/pubmed/32460523
http://dx.doi.org/10.1089/cap.2019.0176

Ejemplares similares